Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination - Test2 - elhamkhani - TriplyDB

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

http://www.wikidata.org/entity/Q24646818

about

Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV Synthetic DNA vaccine strategies against persistent viral infections Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.α1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines DNA vaccines against human immunodeficiency virus type 1.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species Genes that induce immunity--DNA vaccines.Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.DNA vaccines for viral diseases.Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses.Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.DNA/MVA Vaccines for HIV/AIDS DNA vaccines: future strategies and relevance to intracellular pathogens.Non-human primate models for AIDS vaccine research.

P2860

Q24644853-D2C2B720-9AFD-4792-ABAB-D1A9149BD2F3 Q24797123-6B661AC2-212D-4880-AC35-1FBC0A7AF226 Q27016078-FF17A470-9FA8-4017-8BC8-5DA8778D6FDD Q27469642-0DBC702C-6199-479C-A3ED-CA0903E89A95 Q27469682-0B3E5AE9-B572-48AA-9748-0EE60858E6FC Q28731975-B1B7D101-ABFB-4DA3-8F38-E4221D09B435 Q28749120-E20E404C-09BB-4CDC-9AB0-0F2A0F99CDEA Q30332833-D387406F-21D4-406E-B4A6-EEF09CF566CE Q30342130-F70FA3A0-61D4-4060-880A-C643AF759E95 Q30379200-9BF744AE-DA68-4170-9A81-931CFEAC6068 Q33587515-96B46F25-3A7D-49E4-83B5-FD009F4D2C06 Q33641393-ADBFB6E9-DE87-42C2-878B-3ACC487FCCC2 Q33645053-91340417-50A3-4A53-A797-6F7F453CCDD3 Q33646672-A5D8C5C3-8FF1-484E-A22E-6A0DB99A986D Q33649842-74C7D7BE-E1C2-4831-8F88-A1CF0F7304FC Q33784952-91F2D3FD-F9C6-4914-966E-1D9B3FE96FB5 Q33785383-1BE43AE5-FE70-44E7-BED6-9C9E6CC4D6B1 Q33786257-B9A41303-FC9E-4C16-BD68-AA8580BCB2F7 Q33787271-2C3AE610-3C6E-4B9B-8B9F-CB5CA7522589 Q33801810-8A46FB76-8655-47BE-8B17-58A7D0DCA93F Q33809753-5EB26118-44D4-4FC2-96FB-8B4398E0C094 Q33811681-086BE611-7E1D-438A-8F25-C8C40FE46E43 Q33819493-2AFEE671-C86B-4AB7-ADDF-7660EB82AF2D Q33839402-A86671EF-6099-46B7-92EB-F71B7FF19A08 Q33842383-A9F8F93F-7EB8-4EDB-A6D7-D939F1086E25 Q33843103-F5225837-5B04-4CBF-8E19-ADDB9B218D2B Q33843258-6454B840-B6BE-41D1-B29C-E0582C9215B4 Q33867634-8C5B379B-92BE-4299-A713-29901A786965 Q33874534-48DA04E4-17FE-4BE5-A655-3EEEBA8E4989 Q33911670-F55A01AE-B39E-452A-B150-6AA4FF5FEEED Q33961878-B210E793-1B84-4613-B252-FCA84C529837 Q34004513-B5FB1667-9581-44B3-83A6-C8B73D0CB9B1 Q34007261-658A727D-704C-447B-9AAB-71132450067E Q34034104-A0A81438-23F6-47CA-AD36-F8AD62AF7F77 Q34103170-2FC5C642-0C30-4B75-9547-7E26DB0B41B5 Q34123950-BBCD6472-0243-4DB7-A91C-462D900C13EB Q34333402-26957D2E-5400-49FF-8F38-720658C92D03 Q34492802-B6D10646-119B-483C-952E-2FD8B3514583 Q34570728-E64775F3-56DA-42AB-B2F5-1F116529F801 Q34715769-7FDCFD68-2082-4D27-8CD2-268AE1A00381

P2860

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

http://www.wikidata.org/entity/Q24646818

description

1997 nî lūn-bûn

@nan

1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@ast

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@en

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@nl

type

label

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@ast

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@en

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@nl

prefLabel

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@ast

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@en

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@nl

P1433

Q24646818-EB1E5CE4-9643-4869-9C30-2B3EA3D6F036

P1476

Q24646818-AD9FD031-096A-4599-AF7E-7758B9B1DBFF

P2093

Q24646818-1858EF50-903F-441F-A56F-4EBF0868E23A

Q24646818-1DB983EC-E90A-4BA9-91B4-4BA85A4434F0

Q24646818-2C1C5DAD-9407-4859-B8B7-AA00A985C00A

Q24646818-2FF52D5F-4A83-4BA7-B76F-A383D03558DE

Q24646818-30E69F1B-0462-42FF-90DF-EABD9F248A1F

Q24646818-312AA43F-F7C0-4ED8-9E1C-B4826AC99889

Q24646818-34707882-3D5E-44CB-A6FB-32060AC65B34

Q24646818-487549F9-561E-40F1-91E4-7E82647019BD

Q24646818-59855D26-4E5C-4733-86D2-1CBDBB23DC06

Q24646818-6152A201-635B-4780-8F0B-3E4130FDD175

P2860

Q24646818-02517DF9-99FA-4705-A8D0-DED444C2E974

Q24646818-07F8573E-5789-4789-914B-41916A5D8C50

Q24646818-0A505D11-442E-4F8A-AAA5-AC2549741B12

Q24646818-0C89C01B-030D-46FC-BDFE-743D4FEA2939

Q24646818-230EA982-A61F-4089-A3BD-CE6EFC7DEE95

Q24646818-261E3A12-5ABA-4401-9362-44DBF5D727EE

Q24646818-388035BC-D0B9-4B9E-A459-E03A266128BE

Q24646818-473F2470-2868-420C-AA9C-D5853876CCC1

Q24646818-5387BA6C-4E90-4F82-A6D2-6B0855598890

Q24646818-59EB00A6-4A25-4776-9E1E-F514ACCA136E

P304

Q24646818-81C2C1EC-DCDD-4212-AE9E-A370C1DA3067

P31

Q24646818-97D8CD65-C33A-4ED0-B967-45DFC38ABC23

P3181

Q24646818-CEBD4F36-11EE-4BE2-9DEC-53576A0D3A8E

P356

Q24646818-631669FA-D1E8-4831-B42A-3E79AF2B7FA1

P407

Q24646818-7CF07161-6697-4856-BFE6-2754763F520C

P433

Q24646818-E3E8ED83-9A2D-4E9D-A763-D81561BDA75D

P478

Q24646818-B39C5889-3228-4A9D-9E8F-C5071E0BC281

P577

Q24646818-9676C75B-78A8-40EA-A39A-BA8077113E49

P5875

Q24646818-B056AC0A-DAEC-4ED8-8D24-1019130F8D22

P698

Q24646818-6BA1EFC6-2010-48BB-B9D0-517CC8809330

P921

Q24646818-E89DF648-1C00-4645-AAC1-082EBD4CB811

P932

Q24646818-23733FA4-E879-4655-9346-EED57A4C6A6A

P3181

P356

PNAS.94.17.9378

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Potent, protective anti-HIV im ...... e DNA plus protein vaccination

@en

P2093

C I Lord

http://www.w3.org/2001/XMLSchema#string

C Lekutis

http://www.w3.org/2001/XMLSchema#string

D C Freed

http://www.w3.org/2001/XMLSchema#string

D C Montefiori

http://www.w3.org/2001/XMLSchema#string

H C Perry

http://www.w3.org/2001/XMLSchema#string

J W Shiver

http://www.w3.org/2001/XMLSchema#string

L K Handt

http://www.w3.org/2001/XMLSchema#string

M A Liu

http://www.w3.org/2001/XMLSchema#string

M Alroy

http://www.w3.org/2001/XMLSchema#string

M E Davies

http://www.w3.org/2001/XMLSchema#string

P2860

DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge.

High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors.

An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys

Gene inoculation generates immune responses against human immunodeficiency virus type 1

P304

9378-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3762185

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.94.17.9378

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

1997-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13962698

http://www.w3.org/2001/XMLSchema#string

P698

9256490

http://www.w3.org/2001/XMLSchema#string

P921

P932

23198

http://www.w3.org/2001/XMLSchema#string